Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax plus /- azacitidine in IDH1-mutated hematologic malignancies.
Lachowiez CA., Borthakur G., Loghavi S., Zeng Z., Kadia TM., Masarova L., Takahashi K., Tippett GD., Naqvi K., Bose P., Jabbour E., Ravandi F., Daver NG., Garcia-Manero G., Stoilova B., Vyas P., Kantarjian HM., Konopleva M., Dinardo CD.